Vivien Reinecke1*, Daniel Hofbauer, MSc, BSc2*, Jörg-Thomas Bittenbring, MD3*, Christopher Lischer, MSc4*, Johannes Berges1*, Gina Nusser1*, Katrin Bitterer, MTA4*, Simon Voelkl, PhD5,6,7*, Dimitrios Mougiakakos, MD8, Andreas Mackensen, MD5,9* and Heiko Bruns10*
1University Hospital Erlangen, Erlangen, Germany
2Department of Internal Medicine 5 – Hematology/Oncology, University Hospital Erlangen, Erlangen, DEU
34Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg, Homburg, DEU
4Department of Internal Medicine 5 – Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany
5Bavarian Cancer Research Center (BZKF), Erlangen, Germany
6Department of Internal Medicine 5, Hematology and Oncology, University Hospital Erlangen, Erlangen, Germany
7Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany
8Health-Campus Immunology, Infectiology, and Inflammation (GC-I3), Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany
9Department of Internal Medicine 5 - Hematology and Oncology, University Hospital of Erlangen, Erlangen, Germany
10University Hospital Erlangen, Nürnberg, Germany